ClinicalTrials.Veeva

Menu

The Analgesic Effect of Pericapsular Nerve Group Block With Lateral Femoral Cutaneous Nerve Block and Pericapsular Nerve Group Block With Supra-inguinal Fascia Iliaca Block in Hip Hemiarthroplasty

A

Ain Shams University

Status

Completed

Conditions

Pericapsular Nerve Group Block
Hip Hemiarthroplasty
Lateral Femoral Cutaneous Nerve Block
Supra-inguinal Fascia Iliaca Block

Treatments

Other: Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)
Other: Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)

Study type

Interventional

Funder types

Other

Identifiers

NCT06577103
FMASU MD345/2023

Details and patient eligibility

About

The aim of this study is to investigate the efficiency of preoperative and post-operative analgesia by pericapsular nerve group block (PENG) block with supra-inguinal fascia iliaca block (SIFIC) block compared with PENG block with lateral femoral cutaneous nerve block (LFCN) block in ease of giving a sitting position for spinal anesthesia and reducing narcotic consumption during the first 24 hour post-operatively and functional recovary by using the Visual analogue scale (VAS) of pain.

Full description

The established practice to decrease pain using opioids in hip fracture surgery may result in compromised outcomes in the frail and elderly population with nausea-vomiting, constipation, delirium and respiratory depression. This popularized the regional analgesic techniques in the surgical treatment of hip fractures. Femoral nerve (FN) and supra-inguinal fascia iliaca block (SIFIC) block are documented to provide good peri-operative analgesia with reduced need for opioids.

The latest pericapsular nerve group block (PENG) block, is an interfacial plane block targeting the articular branches of the femoral, obturator (ON) and accessory obturator nerves (AON) at the hip.

An ability to perform in supine positioning, which is especially important in patients with acute hip fractures or chronic pain is an indigenous advantage of PENG block. Due to the blockade of only sensory articular branches, substantial motor weakness is unexpected. But exclusive use of PENG block for analgesia in hip fracture patients is not sufficient as it doesn't involve the cutaneous pain-generating area supplied by the lateral femoral cutaneous nerve block (LFCN).

Enrollment

60 patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 40-80 years.
  • Sex: Both sexes.
  • American Society of Anaesthesiologists (ASA) Physical Status Class I, II, and III.
  • Scheduled for hip hemiarthroplasty under general anesthesia.

Exclusion criteria

  • Declining to give a written informed consent.
  • History of allergy to the medications used in the study.
  • Contraindications to regional anesthesia (including patient refusal, coagulopathy and local infection).
  • Psychiatric disorders or narcotic abusers.
  • Significant cognitive dysfunction.
  • American Society of Anesthesiologists (ASA) Physical Status Class IV.
  • Renal insufficiency (to avoid local anesthetic or nalbuphine metabolites adverse effect)
  • Opioid abuser patients
  • Pregnancy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

60 participants in 2 patient groups

Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)
Experimental group
Description:
Patients will receive pericapsular nerve group (PENG) block with supra-inguinal fascia iliaca (SIFIC) block.
Treatment:
Other: Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)
Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)
Experimental group
Description:
Patients will receive pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block.
Treatment:
Other: Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)

Trial contacts and locations

1

Loading...

Central trial contact

Moussa E Elshabrawy, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems